Page last updated: 2024-11-07

3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID104739
CHEBI ID184401
SCHEMBL ID9472000
MeSH IDM0132055

Synonyms (36)

Synonym
3,4,8-trimethylimidazo(4,5-f)quinoxalin-2-amine
di-meiqx
4,8-dimethyl iqx
3,4,8-trimethyl-3h-imidazo(4,5-f)quinoxalin-2-amine
4,8-dimethyl-iqx
2-amino-3,4,8-trimethylimidazo(4,5-f)quinoxaline
brn 5344583
dimethyl-iqx
3h-imidazo(4,5-f)quinoxalin-2-amine, 3,4,8-trimethyl-
ccris 6408
FT-0662096
CHEBI:184401
95896-78-9
3,4,8-trimethylimidazo[4,5-]quinoxalin-2-amine
3,4,8-trimethyl-1h,2h,3h-imidazo[4,5-f]quinoxalin-2-imine
3,4,8-trimethylimidazo[4,5-f]quinoxalin-2-amine
3,4,8-meiqx
4,8-dimeiqx
unii-yra7g7wu6p
yra7g7wu6p ,
FT-0611030
2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline
2-amino-3,4,8-trimethyl-3h-imidazo(4,5-f)quinoxaline
4-methyl meiqx
SCHEMBL9472000
2-amino-3,4,8-trimethyl-3h-imidazo[4,5-f]quinoxaline
1216997-87-3
3,4,8-trimethyl-3h-imidazo[4,5-f]quinoxalin-2-amine
DTXSID90242018 ,
AKOS027379693
mfcd00269903
3,4,8-trimethyl-3h-imidazo[4,5-f]quinoxalin-2-amine, 9ci
4,8-di-meiqx
2-amino-3,4,8-trimethylimidazo[4,5-f ]quinoxaline
Q27294682
dtxcid90164509

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
"Mutagenic activity detected in beef extracts and in fried beef heated for varying periods of time was purified and then analysed by high-performance liquid chromatography in combination with mass spectrometry (LC-MS)."( Analysis of mutagenic heterocyclic amines in cooked beef products by high-performance liquid chromatography in combination with mass spectrometry.
Aeschbacher, HU; Bur, H; Huynh-Ba, T; Milon, H; Turesky, RJ, 1988
)
0.27

Dosage Studied

ExcerptRelevanceReference
" Urine samples and faecal extracts from 3H-PhIP or 2-14C-DiMeIQx dosed rats were analysed by these ELISA assays, and high correlations between radioactivity and response in the ELISA assays were observed."( Antibodies to the food mutagens, 2-amino-1-methyl-6-phenylimidazo [4,5-b]pyridine and 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline: useful for immunoassay and immunoaffinity chromatography of biological samples.
Dragsted, LO; Frandsen, H; Grivas, S; Larsen, JC, 1995
)
0.29
" 32P-Postlabelling analysis of calf thymus DNA modified with 4,8-DiMeIQx in vitro and liver DNA from rats dosed with 50 mg/kg 4,8-DiMeIQx showed a similar adduct pattern."( Formation of DNA adducts by the food mutagen 2-amino-3,4,8-trimethyl-3H-imidazo[4,5-f]quinoxaline (4,8-DiMeIQx) in vitro and in vivo. Identification of a N2-(2'-deoxyguanosin-8-yl)-4,8-DiMeIQx adduct.
Andersson, R; Dragsted, LO; Frandsen, H; Grivas, S; Larsen, JC; Turesky, RJ, 1994
)
0.29
" HPLC analysis of samples of urine and extracts from faeces, from rats dosed with [3H]PhIP-dG, showed that approximately 90% of the radioactivity co-eluted with PhIP-dG, indicating that PhIP-dG is excreted unmetabolized."( Excretion of DNA adducts of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and 2-amino-3,4,8-trimethylimidazo[4,5-f]quinoxaline, PhIP-dG, PhIP-DNA and DiMeIQx-DNA from the rat.
Frandsen, H, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
quinoxaline derivativeAny naphthyridine derivative that is a derivative of quinoxaline (1,4-naphthyridine).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (59)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (11.86)18.7374
1990's20 (33.90)18.2507
2000's19 (32.20)29.6817
2010's13 (22.03)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.60 (24.57)
Research Supply Index4.16 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (3.28%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other59 (96.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]